The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...

The outcome of the 2024 U.S. presidential election is poised to affect the biotechnology sector, as both major parties present policy proposals that could reshape drug pricing, regulation, and ...

Among 198 patients with HIV who received a kidney from a deceased donor, risk of a safety event within a median of 2.2 years was similar between the two groups (adjusted HR 1.00, 95% CI 0.73-1.38), ...

Industry Veterans Appointed to Drive Strategic Vision of the Specialized Investment FundBOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- NYBC Ventures LLC (“NYBC Ventures”), a specialized fund focused on ...

Despite a 7% YTD gain, IBB ETF has underperformed the S&P 500, which is up 21%, and shows negative alpha. Read more on IBB ...

Gilead will pay a fee of $315 million if it takes the option, and up to $1.15 billion in future milestone payments. It will also provide Pionyr with additional funding to develop PY314 and PY159 ...

Gilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – even though the biotech’s lead drug candidate is already partnered ...

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the ...